-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceuticals.
com technical article] A while ago, a video of "the most gentle medical insurance negotiating sister" exploded everyone's circle of friends
.
In the 2021 national medical insurance drug list negotiation, the price of a certain rare disease drug will drop from more than 50,000 yuan to more than 30,000 yuan
.
Among them, we have seen the government's attention to the life and health of the people, and also the survival pressure of pharmaceutical companies
.
However, for people in the pharmaceutical industry, they are always faced with many challenges from R&D costs and more refined regulatory requirements, which are beneficial to the people and take into account their own profits
.
In this issue of Shixiangxuetang, Xiaoshi is honored to invite Dr.
Zhou Xinhua, founder and president of Jiahe Biopharmaceutical Co.
, Ltd.
, and Mr.
Wang Peidong, general manager of the life science industry of Schneider Electric's industrial automation end-user business, to discuss with us the opportunities and opportunities facing the pharmaceutical industry today.
challenges, and how Shijia helps industry customers overcome difficulties and create greater business value
.
It is necessary to do a good job of medicine and control costs.
According to the data of the Ministry of Industry and Information Technology, China's pharmaceutical industry has grown rapidly in recent years, with an average annual growth rate of about 10%.
The entire industry has entered a new outbreak period, bringing more opportunities for pharmaceutical companies
.
Dr.
Zhou, who has worked in the pharmaceutical industry for many years, has deeply felt the changes in recent years, and is constantly thinking about solutions to the challenges faced by the industry: from small-molecule chemical drugs, to macromolecular fusion proteins, to current cell products, and after the epidemic mRNA becomes the new drug spot
.
In such a situation of rapid iteration, how to automate and intelligentize pharmaceutical companies? For the production of multiple batches of small batches, should we continue to use stainless steel tanks or choose disposable reaction bags? How to achieve flexible production? In the face of increasingly strict supervision, how to achieve information connectivity and ensure data integrity and consistency? How to ensure the traceability of the upstream and downstream and the whole life cycle of drug production? Is it possible to reduce the overall cost through the introduction of digitalization for the expensive human and resource costs in the development of new drugs? It is necessary to do a good job of medicines, but also to control costs, and at the same time, environmental issues must be taken into account.
How should the relationship between China and China be balanced? In Shijia's view, green intelligent manufacturing is an important way to solve the above challenges
.
Shijia is deeply involved in the field of life sciences, providing customers in the life sciences industry with a package of solutions from solutions to services, which covers the entire life cycle from digital transformation consulting, detailed engineering design, computerized system verification services, digital delivery to operation and maintenance services.
The service content of the company creates value for customers in terms of safety and compliance, stability and reliability, efficiency and flexibility, and green and low carbon
.
Schneider Electric EcoStruxure™ solution architecture provides complete automation and digital solutions for the pharmaceutical industry in the fields of biopharmaceuticals, preparations, APIs, etc.
, and uses a factory-level big data platform and various applications based on unified platforms and models.
The implemented solution and reasonable cost performance help realize the intelligent manufacturing of pharmaceutical factories, and with the powerful functions of AVEVA, it can realize the operation management covering the whole project and the whole life cycle of the factory
.
Let pharmaceutical companies improve production efficiency and reduce energy consumption while taking into account their own interests
.
Digital empowerment, building a smart pharmaceutical with compliance and efficiency, this issue of "Shixiang Xuetang" will take you to explore the essence!
com technical article] A while ago, a video of "the most gentle medical insurance negotiating sister" exploded everyone's circle of friends
.
In the 2021 national medical insurance drug list negotiation, the price of a certain rare disease drug will drop from more than 50,000 yuan to more than 30,000 yuan
.
Among them, we have seen the government's attention to the life and health of the people, and also the survival pressure of pharmaceutical companies
.
However, for people in the pharmaceutical industry, they are always faced with many challenges from R&D costs and more refined regulatory requirements, which are beneficial to the people and take into account their own profits
.
In this issue of Shixiangxuetang, Xiaoshi is honored to invite Dr.
Zhou Xinhua, founder and president of Jiahe Biopharmaceutical Co.
, Ltd.
, and Mr.
Wang Peidong, general manager of the life science industry of Schneider Electric's industrial automation end-user business, to discuss with us the opportunities and opportunities facing the pharmaceutical industry today.
challenges, and how Shijia helps industry customers overcome difficulties and create greater business value
.
It is necessary to do a good job of medicine and control costs.
According to the data of the Ministry of Industry and Information Technology, China's pharmaceutical industry has grown rapidly in recent years, with an average annual growth rate of about 10%.
The entire industry has entered a new outbreak period, bringing more opportunities for pharmaceutical companies
.
Dr.
Zhou, who has worked in the pharmaceutical industry for many years, has deeply felt the changes in recent years, and is constantly thinking about solutions to the challenges faced by the industry: from small-molecule chemical drugs, to macromolecular fusion proteins, to current cell products, and after the epidemic mRNA becomes the new drug spot
.
In such a situation of rapid iteration, how to automate and intelligentize pharmaceutical companies? For the production of multiple batches of small batches, should we continue to use stainless steel tanks or choose disposable reaction bags? How to achieve flexible production? In the face of increasingly strict supervision, how to achieve information connectivity and ensure data integrity and consistency? How to ensure the traceability of the upstream and downstream and the whole life cycle of drug production? Is it possible to reduce the overall cost through the introduction of digitalization for the expensive human and resource costs in the development of new drugs? It is necessary to do a good job of medicines, but also to control costs, and at the same time, environmental issues must be taken into account.
How should the relationship between China and China be balanced? In Shijia's view, green intelligent manufacturing is an important way to solve the above challenges
.
Shijia is deeply involved in the field of life sciences, providing customers in the life sciences industry with a package of solutions from solutions to services, which covers the entire life cycle from digital transformation consulting, detailed engineering design, computerized system verification services, digital delivery to operation and maintenance services.
The service content of the company creates value for customers in terms of safety and compliance, stability and reliability, efficiency and flexibility, and green and low carbon
.
Schneider Electric EcoStruxure™ solution architecture provides complete automation and digital solutions for the pharmaceutical industry in the fields of biopharmaceuticals, preparations, APIs, etc.
, and uses a factory-level big data platform and various applications based on unified platforms and models.
The implemented solution and reasonable cost performance help realize the intelligent manufacturing of pharmaceutical factories, and with the powerful functions of AVEVA, it can realize the operation management covering the whole project and the whole life cycle of the factory
.
Let pharmaceutical companies improve production efficiency and reduce energy consumption while taking into account their own interests
.
Digital empowerment, building a smart pharmaceutical with compliance and efficiency, this issue of "Shixiang Xuetang" will take you to explore the essence!
